Company Description
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States.
The company’s lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction.
In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention.
Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
| Country | United States |
| Founded | 2016 |
| IPO Date | Oct 16, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 244 |
| CEO | Bobak Azamian |
Contact Details
Address: 15440 Laguna Canyon Road, Suite 160 Irvine, California 92618 United States | |
| Phone | 949 409 1801 |
| Website | tarsusrx.com |
Stock Details
| Ticker Symbol | TARS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001819790 |
| CUSIP Number | 87650L103 |
| ISIN Number | US87650L1035 |
| Employer ID | 81-4717861 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Bobak R. Azamian M.D. | Co-Founder, President, Chief Executive Officer and Chairman |
| Dr. Seshadri Neervannan Ph.D. | Chief Operating Officer |
| David Nakasone | Head of Investor Relations |
| Dr. Bryan Wahl J.D., M.D. | General Counsel and Corporate Secretary |
| Adrienne Kemp | Senior Director of Corporate Communications |
| Matthew Rossen M.B.A. | Vice President of Marketing |
| Scott Youmans | Vice President of Sales |
| Dianne C. Whitfield M.S.W. | Chief Human Resources Officer |
| Aziz Mottiwala M.B.A. | Chief Commercial Officer |
| Cara Miller | Senior Vice President of Corporate Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 6, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 5, 2024 | 8-K | Current Report |